Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of HKD 12.45 [2][9] Core Insights - The company reported a revenue of HKD 14.256 billion for 2025, representing a year-on-year increase of 20.8%. Adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is experiencing significant growth, with revenue surpassing HKD 12.5 billion, compared to HKD 2.2 billion in 2024. The new products have received positive consumer feedback, contributing to market share gains [9] - The vaporization business benefits from stricter industry regulations, enhancing the company's competitive advantage as a leading electronic vaporization device manufacturer [9] Financial Summary - For 2025, the company achieved total revenue of HKD 14.256 billion, with a projected growth rate of 20.8% for the year. The adjusted net profit is expected to be HKD 1.064 billion, with a decline of 18.4% year-on-year [5][10] - The company anticipates continued revenue growth, with projections of HKD 16.700 billion in 2026, HKD 19.977 billion in 2027, and HKD 23.011 billion in 2028 [5][10] - The adjusted net profit is forecasted to recover to HKD 1.265 billion in 2026, HKD 1.850 billion in 2027, and HKD 2.372 billion in 2028, with corresponding P/E ratios of 39, 27, and 21 respectively [5][10]

Investment Rating - The report maintains a "Strong Buy" rating for Smoore International (06969.HK) with a target price of HKD 12.45 [2][9] Core Insights - In 2025, Smoore International achieved revenue of HKD 14.256 billion, representing a year-on-year increase of 20.8%. The adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is expanding, contributing significantly to revenue growth, with HNB revenue surpassing HKD 1.25 billion in 2025, compared to HKD 220 million in 2024. The company is expected to continue supporting strategic customers in promoting HNB products globally [9][10] - The vaping business benefits from stricter industry regulations, enhancing the market position of compliant companies like Smoore. The ODM (Original Design Manufacturer) business generated revenue of HKD 11.34 billion, up 21.7% year-on-year, with notable growth in Europe and the U.S. markets [9][10] Financial Summary - Total revenue for 2025 is projected at HKD 14.256 billion, with expected growth rates of 17.1%, 19.6%, and 15.2% for 2026, 2027, and 2028 respectively [5][10] - The adjusted net profit for 2025 is estimated at HKD 1.064 billion, with a projected growth rate of -18.4% for 2026, followed by 18.9% and 46.2% for 2027 and 2028 respectively [5][10] - The company’s gross margin for 2025 is reported at 34.1%, down 3.3 percentage points year-on-year, primarily due to a higher proportion of lower-margin products [9][10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [10] Core Insights - The company is expected to achieve revenue of 14.256 billion HKD and adjusted net profit of 1.530 billion HKD in 2025, representing a year-on-year increase of 21% and 1% respectively [2][7] - The company plans to distribute a dividend of 0.4 HKD per share for the year 2025, resulting in a dividend payout ratio of 234.4% [2][7] - The HNB (Heat-not-Burn) and vaping segments are performing positively, with HNB revenue expected to grow significantly due to new product launches in key markets [11] Revenue Summary - For 2025, the company anticipates a total revenue of 14.256 billion HKD, with a breakdown of 8.243 billion HKD in H2 and 4.046 billion HKD in Q4, showing year-on-year growth rates of 22% and 16% respectively [2][7] - The TOB (Tobacco Operating Business) is projected to contribute 80% of total revenue, with a 22% increase in revenue, while the TOC (Tobacco Operating Company) is expected to grow by 18% [11] Profitability Summary - The gross margin is expected to decline by 3.3 percentage points to 34.1% due to changes in product mix, with increased costs in stock-based compensation and legal services impacting profitability [11] - The company is projected to achieve adjusted net profits of 1.158 billion HKD, 2.020 billion HKD, and 2.770 billion HKD for the years 2026 to 2028, with corresponding PE ratios of 31, 24, and 18 [11] Long-term Outlook - The long-term outlook for HNB and vaping products is positive, with expected compound annual growth rates of 11.5% from 2025 to 2030 [11] - The company is also exploring new business opportunities in medical vaping and other specialized applications, with FDA certification for its manufacturing facility in the U.S. [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 14.26 billion yuan for 2025, representing a year-on-year growth of 20.83%. The net profit was 1.06 billion yuan, down 18.37% year-on-year, but the adjusted net profit was 1.53 billion yuan, up 1.3% year-on-year [7] - The HNB (Heat Not Burn) business is expected to ramp up, with significant growth in the electronic atomization segment. The company is also expanding into new business areas such as medical and beauty atomization, which are anticipated to provide long-term growth opportunities [7] - The company is positioned as a global leader in atomization technology, with a multi-business matrix that is steadily advancing despite tightening regulatory policies [7] Financial Summary - Total revenue projections for the company are as follows: - 2024: 11.80 billion yuan - 2025: 14.26 billion yuan - 2026: 16.62 billion yuan - 2027: 19.77 billion yuan - 2028: 23.34 billion yuan - The projected net profit for the years 2026 to 2028 is as follows: - 2026: 1.26 billion yuan - 2027: 1.88 billion yuan - 2028: 2.79 billion yuan - The earnings per share (EPS) is projected to be: - 2024: 0.21 yuan - 2025: 0.17 yuan - 2026: 0.20 yuan - 2027: 0.30 yuan - 2028: 0.45 yuan [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 14.26 billion yuan for 2025, representing a year-on-year growth of 20.83%. However, the net profit was 1.06 billion yuan, down 18.37% year-on-year. Adjusted net profit was 1.53 billion yuan, showing a slight increase of 1.3% [7] - The HNB (Heat Not Burn) business is expected to ramp up, while the electronic atomization segment is recovering steadily. The company is expanding its product matrix and has launched HNB products in various international markets, aiming for increased market share [7] - The company is positioned as a global leader in atomization technology, with ongoing growth opportunities in electronic atomization and new business ventures in medical and beauty atomization [7] Financial Projections - Total revenue projections for the company are as follows: 2024A: 11.8 billion yuan, 2025A: 14.26 billion yuan, 2026E: 16.62 billion yuan, 2027E: 19.77 billion yuan, and 2028E: 23.34 billion yuan [1] - The projected net profit for 2026 is 1.26 billion yuan, with further increases expected in subsequent years, reaching 2.78 billion yuan by 2028 [1] - The earnings per share (EPS) is forecasted to be 0.21 yuan for 2024, decreasing to 0.17 yuan for 2025, and then gradually increasing to 0.45 yuan by 2028 [1] Business Performance - The company’s self-owned brand and B2B business segments reported revenues of 29.12 billion yuan and 113.44 billion yuan respectively, with year-on-year growth rates of 17.6% and 21.7% [7] - The HNB revenue reached 12.87 billion yuan, showing a significant year-on-year increase of 475.4%, while European and American atomization revenues grew by 18.5% and 2.1% respectively [7] - The adjusted net profit margin for the second half of 2025 was 9.6%, with a year-on-year decrease of 1.6 percentage points, indicating a narrowing decline compared to the first half [7]

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of HKD 16.00 [1] Core Insights - The company achieved a revenue of RMB 14.256 billion in 2025, representing a year-on-year increase of 20.8%, with adjusted profit reaching RMB 1.53 billion, up 1.3% year-on-year. The growth was driven by the recovery of the aerosol business in Europe and the U.S., as well as the ramp-up of the HNB (Heated Not Burned) business [1][2] - The report anticipates continued recovery in the aerosol business and further progress in the HNB sector, supported by a multi-client and multi-product strategy [1][3] Summary by Sections Aerosol Business - The ToB (Business to Business) segment generated revenue of RMB 10.058 billion in 2025, a 10.5% increase year-on-year, benefiting from regulatory enforcement in Europe and the U.S. The revenue breakdown includes RMB 5.77 billion from Europe, RMB 4.07 billion from the U.S., and RMB 210 million from mainland China [2] - The ToC (Business to Consumer) segment achieved revenue of RMB 2.911 billion, up 17.6% year-on-year, with significant growth in overseas markets driven by the VAPORESSO brand [2] HNB Business - The HNB segment reported revenue of RMB 1.29 billion, a staggering increase of 475.4% year-on-year, driven by the launch of high-end products in key markets [3] - The company plans to expand the Glo Hilo product line into more markets and accelerate the commercialization of other HNB technology platforms in 2026 [3] Financial Performance - The gross margin for 2025 was 34.1%, down 3.3 percentage points year-on-year, primarily due to changes in business structure and rising raw material costs. The total expense ratio decreased to 23.0% in the second half of 2025 [4] - Adjusted net profit margin for 2025 was 10.7%, reflecting a decline of 2.1 percentage points year-on-year [4] Profit Forecast and Valuation - The adjusted net profit forecasts for 2026, 2027, and 2028 are RMB 1.652 billion, RMB 2.253 billion, and RMB 2.841 billion, respectively. The adjusted EPS for these years is projected to be RMB 0.27, RMB 0.36, and RMB 0.46 [5] - The company is assigned a target PE of 40 times for 2027, leading to a target price of HKD 16.00, based on the expected growth in the HNB and aerosol businesses [5]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company has achieved record-high annual revenue, with multiple business segments showing positive progress, including heated non-combustion products, vaporized e-cigarettes, and medical aerosol business [2][9] - The company is expected to maintain a strong growth trajectory, with projected revenues increasing from 11.8 billion RMB in 2024 to 21.3 billion RMB by 2028, reflecting a compound annual growth rate (CAGR) of approximately 14% [3][10] - The net profit forecast for 2026-2028 is adjusted to 1.05 billion RMB, 1.82 billion RMB, and 2.18 billion RMB respectively, indicating a significant recovery in profitability [9] Financial Summary - Total revenue is projected to grow from 11,799 million RMB in 2024 to 21,276 million RMB in 2028, with year-on-year growth rates of 6%, 21%, 15%, 14%, and 14% respectively [3][10] - Gross profit is expected to increase from 4,412 million RMB in 2024 to 7,245 million RMB in 2028, with a gross margin of 34.1% in 2025 [3][10] - The company's net profit is forecasted to decline to 1,052 million RMB in 2026 before rebounding to 1,820 million RMB in 2027 and 2,180 million RMB in 2028, with a notable increase in profit margins in the later years [3][10] Business Performance - In the second half of 2025, revenue from enterprise customers reached 6.605 billion RMB, a year-on-year increase of 22%, while retail customer revenue was 1.637 billion RMB, up 23% year-on-year [9] - The company’s HNB (Heated Non-Combustion) revenue exceeded 1.2 billion RMB in 2025, supported by the successful launch of high-end products in key markets [9] - The traditional vaporization business is expected to benefit from global regulatory changes, enhancing brand market share [9] Market Position - The company is positioned as a core supplier in the heated non-combustion industry, benefiting from long-term R&D investments that create a strong technological moat [9] - The company is expected to achieve a target price of 12.00 HKD based on a PE ratio of 65.0X for 2026, reflecting a premium valuation due to its leading market position and growth potential [9]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong performance relative to the benchmark index [13]. Core Insights - The company reported a revenue of 14.256 billion yuan for 2025, representing a year-on-year growth of 20.8%, while the net profit was 1.062 billion yuan, down 18.5% year-on-year. Adjusted net profit, excluding share-based payment expenses, was 1.530 billion yuan, reflecting a slight increase of 1.4% [1]. - The growth in revenue is attributed to the contribution from HNB (Heat Not Burn) products, steady growth of proprietary brands, and an increase in market share in Europe. However, profitability faced pressure due to changes in product mix, foreign exchange losses, and additional litigation costs [1][2]. - The company expects to continue supporting strategic clients in promoting high-end HNB products globally, with a projected revenue of over 1.2 billion yuan from HNB products. The medical nebulization segment is anticipated to start contributing to revenue in 2026 [3]. Financial Performance Summary - For the second half of 2025, the company achieved a revenue of 8.243 billion yuan, a year-on-year increase of 21.9%, with a net profit of 569 million yuan, down 8.2% year-on-year. Adjusted net profit for the same period was 795 million yuan, up 5.1% [1]. - The brand business generated 1.637 billion yuan in revenue for the second half of 2025, with significant growth in the U.S. and Europe, while the ODM (Original Design Manufacturer) business saw revenue of 6.605 billion yuan, reflecting a year-on-year increase of 22.3% [2]. - The company’s gross margin for 2025 was 34.1%, down 3.3 percentage points year-on-year, while the adjusted net profit margin was 10.7%, down 2.0 percentage points year-on-year. The sales, management, and financial expense ratios were 6.4%, 9.0%, and 10.7%, respectively [3]. Earnings Forecast - The company forecasts net profits of 1.16 billion yuan, 2.57 billion yuan, and 4.41 billion yuan for 2026, 2027, and 2028, respectively, with corresponding P/E ratios of 45.2X, 20.5X, and 11.9X [4][5].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong performance relative to the benchmark index [1]. Core Insights - The company achieved a revenue of 14.256 billion yuan in 2025, representing a year-on-year growth of 20.8%. The net profit for the same period was 1.062 billion yuan, down 18.5% year-on-year, but adjusted net profit increased by 1.4% to 1.530 billion yuan [1][2]. - The growth in revenue is attributed to the contribution from HNB (Heat Not Burn) products, steady growth of proprietary brands, and an increase in market share in Europe. However, profitability was slightly pressured due to changes in product mix and foreign exchange losses [1][3]. Revenue Breakdown - Brand Business: In the second half of 2025, revenue reached 1.637 billion yuan, up 20.5% year-on-year, with significant contributions from the US and Europe [2]. - ODM Business: Revenue for the same period was 6.605 billion yuan, reflecting a 22.3% increase year-on-year, with Europe showing a remarkable growth of 475.4% in HNB contributions [2][3]. HNB and Medical Segment - HNB revenue surpassed 1.2 billion yuan, with expectations for improved profitability as the proportion of HNB cartridges increases. The medical nebulization segment is anticipated to start contributing to revenue in 2026 [3][4]. Cost Management - The company reported a gross margin of 34.1%, down 3.3 percentage points year-on-year, while the adjusted net profit margin was 10.7%, down 2.0 percentage points. Despite foreign exchange losses and litigation costs, the company has optimized its R&D and sales expense ratios [3][4]. Financial Projections - The company forecasts net profits of 1.16 billion yuan in 2026, 2.57 billion yuan in 2027, and 4.41 billion yuan in 2028, with corresponding P/E ratios of 45.2X, 20.5X, and 11.9X respectively [4][5].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [1]. Core Views - The company achieved a revenue of 14.3 billion HKD in 2025, representing a year-on-year growth of 21%, while the net profit attributable to shareholders was 1.06 billion HKD, down 19% year-on-year [1]. - The company’s dividend for 2025 is set at 0.2 HKD per share, reflecting confidence in future growth [1]. - The report highlights the recovery in the vaping business, driven by regulatory changes and market expansion in the U.S. and Europe, with a notable increase in revenue from self-owned brands [2]. - The HNB (Heated Not Burned) segment shows significant growth potential, with a revenue increase of 476% year-on-year, and plans for further market expansion in 2026 [3]. - The emerging medical and beauty aerosol business is in the exploratory phase, with high R&D investments impacting current performance but promising long-term profitability [3]. - The company is expected to maintain a strong dividend yield of 3.36% in 2025, indicating confidence in its long-term growth trajectory [4]. Summary by Relevant Sections Revenue and Profitability - In 2025, the company reported a revenue of 14.3 billion HKD, with a 22% increase in the second half to 8.2 billion HKD, while the net profit for the same period was 570 million HKD, down 8% [1]. - The adjusted net profit for 2025, excluding stock incentive expenses, was 1.53 billion HKD, reflecting a 1.3% increase year-on-year [1]. Business Segments - The vaping business generated revenues of 7.1 billion HKD in the U.S., 4.1 billion HKD in Europe, and 200 million HKD in China, with year-on-year growth rates of 19%, 2%, and -11% respectively [2]. - The HNB segment achieved a revenue of 1.3 billion HKD, with a year-on-year growth of 476%, and is set to expand into more core markets [3]. - The medical and beauty aerosol segment is preparing for FDA approval and aims to build small-scale production capabilities, with long-term revenue potential [3]. Financial Projections - Revenue projections for 2026-2028 are 16.91 billion HKD, 19.98 billion HKD, and 23.66 billion HKD, with year-on-year growth rates of 18.64%, 18.13%, and 18.42% respectively [4]. - The net profit projections for the same period are 1.65 billion HKD, 2.57 billion HKD, and 3.49 billion HKD, with growth rates of 55.20%, 55.58%, and 35.69% respectively [4]. - The expected EPS for 2025-2027 is 0.27 HKD, 0.41 HKD, and 0.56 HKD, with corresponding P/E ratios of 42, 27, and 20 times [4].